CA
NZ
UK
AU
IND
US
Key HighlightsEli Lilly (NYSE:LLY) opened at about USD 1,365 on Monday, November 9, 2026 and climbed to USD 1,411.82 as healthcare stocks joined the broad market rebound.The stock remains close to its all-time high of about USD 1,450.75, set last week after third-quarter results, …
Key HighlightsThe FDA on November 9, 2026 ordered new warnings on all GLP-1 drugs about non-arteritic anterior ischemic optic neuropathy, or NAION, a rare eye condition that can cause sudden vision loss, affecting products from Eli Lilly (NYSE:LLY) and Novo Nordisk.The agency's review of …
Key HighlightsImmunityBio (NASDAQ:IBRX) fell about 20% on November 9, 2026 to around USD 6.89, from a close of USD 8.64 the previous Friday, with more than twice its averageVolumechanging hands.Third-quarter net productRevenuefrom Anktiva rose 53% to USD 48.7 million, but total revenue of about …
Key HighlightsArrowhead Pharmaceuticals (NASDAQ:ARWR) fell 15.4%, or USD 8.95, to USD 49.21 on November 9, 2026, from a close of USD 58.16 on November 6, onVolumenearly double its average.The company issued no price-sensitive announcement that day, while rival Ionis Pharmaceuticals fell about 27% after …
Key HighlightsNovoCure (NASDAQ:NVCR) said on November 9, 2026 that the FDA issued a not approvable letter for its premarket approval application for Optune Mya in brain metastases from non-small cell lung cancer.The application sought approval for adults whose brain metastases had been treated with …
Hidradenitis suppurativa was the most visible and commercially attractive indication for tibulizumab, a dual inhibitor of the IL-17 and BAFF pathways, and investors had treated it as the company's main near-term value driver. Removing it leaves Zura Bio with programs whose results are further …
Key HighlightsTG Therapeutics (NASDAQ:TGTX) reported third-quarter 2026 globalRevenueof USD 259.9 million on November 9, 2026, up about 60.7% from a year earlier and above the USD 245.5 million consensus.US net product revenue from BRIUMVI, its multiple sclerosis treatment, rose about 52% to USD 232.6 …
Key HighlightsDefinium Therapeutics (NASDAQ:DFTX) reported third-quarter 2026 results on November 9, 2026, holding about USD 241.2 million in cash and USD 805.7 million in short-term investments, roughly USD 1.05 billion combined.Its lead drug, DT120 ODT, a dissolvable form of lysergide, has met its primary …
Several measures pointed in the right direction. Ceva signed 10 intellectual property agreements in the quarter, including three with first-time customers and six for artificial intelligence applications. AI-related licensing reached a record, accounting for more than 35% of licensing revenue, a sign that its …
Key HighlightsZeta Global (NYSE:ZETA) reported third-quarter 2026Revenueof USD 492.7 million on November 9, 2026, up 46.1% from a year earlier and about 4.6% above the USD 471.2 million consensus.GAAPEarningswere USD 0.14 per share against expectations of USD 0.05, and adjusted EBITDA reached USD 121 …
Please wait processing your request...